دورية أكاديمية
أعرض في EDS

Oral Microbiota Alteration and Roles in Epstein-Barr Virus Reactivation in Nasopharyngeal Carcinoma.

التفاصيل البيبلوغرافية
العنوان: Oral Microbiota Alteration and Roles in Epstein-Barr Virus Reactivation in Nasopharyngeal Carcinoma.
المؤلفون: Liao Y; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China., Zhang JB; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China., Lu LX; Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China., Jia YJ; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.; School of Public Health, Sun Yat-Sen University, Guangzhou, China., Zheng MQ; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China., Debelius JW; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden., He YQ; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China., Wang TM; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China., Deng CM; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China., Tong XT; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.; School of Public Health, Sun Yat-Sen University, Guangzhou, China., Xue WQ; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China., Cao LJ; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China., Wu ZY; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China., Yang DW; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.; School of Public Health, Sun Yat-Sen University, Guangzhou, China., Zheng XH; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China., Li XZ; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China., Wu YX; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China., Feng L; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China., Ye W; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden., Mu J; Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA., Jia WH; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.; School of Public Health, Sun Yat-Sen University, Guangzhou, China.
المصدر: Microbiology spectrum [Microbiol Spectr] 2023 Feb 14; Vol. 11 (1), pp. e0344822. Date of Electronic Publication: 2023 Jan 16.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: ASM Press Country of Publication: United States NLM ID: 101634614 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2165-0497 (Electronic) Linking ISSN: 21650497 NLM ISO Abbreviation: Microbiol Spectr Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Washington, DC : ASM Press, 2013-
مواضيع طبية MeSH: Epstein-Barr Virus Infections*/complications , Epstein-Barr Virus Infections*/genetics , Nasopharyngeal Neoplasms*/genetics, Humans ; Nasopharyngeal Carcinoma ; Herpesvirus 4, Human/genetics ; NF-kappa B ; Hydrogen Peroxide ; Tumor Necrosis Factor-alpha
مستخلص: Microbiota has recently emerged as a critical factor associated with multiple malignancies. Nasopharyngeal carcinoma (NPC) is highly associated with Epstein-Barr virus (EBV); the oncovirus resides and is transmitted in the oral cavity. However, the alternation of oral microbiota in NPC patients and its potential link to EBV reactivation and host cell response under the simultaneous existence of EBV and specific bacteria is largely unknown. Here, oral microbiota profiles of 303 NPC patients and controls with detailed clinical information, including serum EBV anti-virus capsid antigen (VCA) IgA level, were conducted. A distinct microbial community with lower diversity and imbalanced composition in NPC patients was observed. Notably, among enriched bacteria in patients, Streptococcus sanguinis was associated with anti-VCA IgA, an indicator of NPC risk and EBV reactivation. By measuring the concentration of its metabolite, hydrogen peroxide (H 2 O 2 ), in the saliva of clinical patients, we found the detection rate of H 2 O 2 was 2-fold increased compared to healthy controls. Further coculture assay of EBV-positive Akata cells with bacteria in vitro showed that S. sanguinis induced EBV lytic activation by its metabolite, H 2 O 2 . Host and EBV whole genome-wide transcriptome sequencing and EBV methylation assays showed that H 2 O 2 triggered the host cell signaling pathways, notably tumor necrosis factor alpha (TNF-α) via NF-κB, and induced the demethylation of the global EBV genome and the expression of EBV lytic-associated genes, which could result in an increase of virus particle release and potential favorable events toward tumorigenesis. In brief, our study identified a characterized oral microbial profile in NPC patients and established a robust link between specific oral microbial alteration and switch of latency to lytic EBV infection status in the oral cavity, which provides novel insights into EBV's productive cycle and might help to further clarify the etiology of NPC. IMPORTANCE EBV is classified as the group I human carcinogen and is associated with multiple cancers, including NPC. The interplays between the microbiota and oncovirus in cancer development remain largely unknown. In this study, we investigate the interactions between resident microbes and EBV coexistence in the oral cavity of NPC patients. We identify a distinct oral microbial feature for NPC patients. Among NPC-enriched bacteria, we illustrated that a specific species, S. sanguinis, associated with elevated anti-IgA VCA in patients, induced EBV lytic activation by its by-product, H 2 O 2 , and activated the TNF-α/NF-κB pathway of EBV-positive B cells in vitro , together with increased detection rate of H 2 O 2 in patients' oral cavities, which strengthened the evidence of bacteria-virus-host interaction in physiological circumstances. The effects of imbalanced microbiota on the EBV latent-to-lytic switch in the oral cavity might create the likelihood of EBV infection in epithelial cells at the nasopharynx and help malignant transition and cancer development.
References: Oxid Med Cell Longev. 2012;2012:717843. (PMID: 22848782)
Front Mol Biosci. 2022 Jan 13;8:757644. (PMID: 35096963)
Nat Methods. 2016 Jul;13(7):581-3. (PMID: 27214047)
Cancer Epidemiol Biomarkers Prev. 2016 Aug;25(8):1201-7. (PMID: 27197279)
Gut. 2017 Jan;66(1):70-78. (PMID: 26408641)
Arch Oral Biol. 1999 Oct;44(10):789-93. (PMID: 10530911)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
Nat Rev Cancer. 2017 May;17(5):271-285. (PMID: 28303904)
Int J Cancer. 2016 Jan 15;138(2):340-7. (PMID: 26235255)
Bioinformatics. 2015 Jan 15;31(2):166-9. (PMID: 25260700)
Int J Cancer. 1987 Jul 15;40(1):69-73. (PMID: 3036721)
Int J Biol Sci. 2016 Oct 18;12(11):1309-1318. (PMID: 27877083)
Nat Biotechnol. 2016 Sep;34(9):942-9. (PMID: 27454739)
J Natl Cancer Inst. 2012 Sep 19;104(18):1396-410. (PMID: 22972969)
Front Cell Infect Microbiol. 2021 May 28;11:658203. (PMID: 34123872)
Lancet. 2019 Jul 6;394(10192):64-80. (PMID: 31178151)
Gut. 2017 Aug;66(8):1441-1448. (PMID: 27797940)
J Pathol. 2013 Nov;231(3):311-22. (PMID: 23868181)
Nat Rev Microbiol. 2019 Nov;17(11):691-700. (PMID: 31477887)
Int J Cancer. 2019 Aug 1;145(3):775-784. (PMID: 30671943)
Cancer Causes Control. 2021 Dec;32(12):1423-1432. (PMID: 34432217)
Bioinformatics. 2014 Aug 1;30(15):2114-20. (PMID: 24695404)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
J Virol. 2014 Feb;88(3):1604-16. (PMID: 24257595)
Nat Med. 2019 Mar;25(3):377-388. (PMID: 30842679)
Cell Host Microbe. 2021 Nov 10;29(11):1649-1662.e7. (PMID: 34637779)
Gut. 2018 Jan;67(1):120-127. (PMID: 27742762)
Int Endod J. 2018 Dec;51(12):1410-1419. (PMID: 29858508)
Curr Top Microbiol Immunol. 2015;391:237-61. (PMID: 26428377)
mSystems. 2020 Jul 7;5(4):. (PMID: 32636333)
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4516-22. (PMID: 20534432)
Radiother Oncol. 2018 Oct;129(1):44-51. (PMID: 29735410)
Gut. 2018 Jun;67(6):1024-1032. (PMID: 28765474)
Ann Oncol. 2016 Aug;27(8):1619-25. (PMID: 27234641)
mSystems. 2018 Dec 4;3(6):. (PMID: 30534599)
J Endod. 2014 Jul;40(7):899-906. (PMID: 24935532)
J Cancer Res Clin Oncol. 2022 Jan;148(1):31-46. (PMID: 34705104)
Bioinformatics. 2010 Jan 1;26(1):139-40. (PMID: 19910308)
Int J Cancer. 2019 Jan 1;144(1):98-109. (PMID: 29978480)
Front Cell Infect Microbiol. 2020 Jan 15;9:476. (PMID: 32010645)
Chin J Cancer. 2016 Aug 15;35(1):78. (PMID: 27527073)
Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):175-9. (PMID: 15611471)
Int J Oral Sci. 2017 Jun;9(2):95-103. (PMID: 28621324)
Cancer Sci. 2015 Sep;106(9):1196-201. (PMID: 26082292)
Nat Rev Cancer. 2016 Dec;16(12):789-802. (PMID: 27687982)
Br J Cancer. 2007 Feb 26;96(4):623-30. (PMID: 17285127)
J Infect Dis. 2019 Jan 9;219(3):400-409. (PMID: 30307559)
Nat Microbiol. 2019 Dec;4(12):2319-2330. (PMID: 31501538)
EBioMedicine. 2018 Apr;30:184-191. (PMID: 29606628)
Nat Genet. 2018 Sep;50(9):1219-1224. (PMID: 30104762)
Nat Methods. 2015 Apr;12(4):357-60. (PMID: 25751142)
Lancet Glob Health. 2020 Feb;8(2):e180-e190. (PMID: 31862245)
Biochem Pharmacol. 2006 Nov 30;72(11):1493-505. (PMID: 16723122)
Int J Infect Dis. 2014 Aug;25:110-5. (PMID: 24878579)
Nat Rev Cancer. 2013 Nov;13(11):800-12. (PMID: 24132111)
Blood. 2006 Apr 15;107(8):3295-302. (PMID: 16380446)
EBioMedicine. 2017 Apr;18:23-31. (PMID: 28216066)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
PLoS One. 2014 Jun 19;9(6):e100360. (PMID: 24945300)
Am J Respir Crit Care Med. 2019 Sep 15;200(6):760-770. (PMID: 30883192)
Gut. 2018 Aug;67(8):1454-1463. (PMID: 28988196)
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441. (PMID: 23189750)
Front Cell Infect Microbiol. 2022 Mar 22;12:831409. (PMID: 35392614)
J Virol. 2004 Jul;78(13):7004-15. (PMID: 15194777)
Gut. 2020 Oct;69(10):1867-1876. (PMID: 32759302)
Nat Biotechnol. 2019 Aug;37(8):852-857. (PMID: 31341288)
Microbiome. 2018 Aug 6;6(1):137. (PMID: 30081949)
فهرسة مساهمة: Keywords: Epstein-Barr virus; H2O2; Streptococcus sanguinis; microbiota-virus interaction; nasopharyngeal carcinoma; oral microbiota
المشرفين على المادة: 0 (NF-kappa B)
BBX060AN9V (Hydrogen Peroxide)
0 (Tumor Necrosis Factor-alpha)
تواريخ الأحداث: Date Created: 20230116 Date Completed: 20230216 Latest Revision: 20231020
رمز التحديث: 20231020
مُعرف محوري في PubMed: PMC9927204
DOI: 10.1128/spectrum.03448-22
PMID: 36645283
قاعدة البيانات: MEDLINE
الوصف
تدمد:2165-0497
DOI:10.1128/spectrum.03448-22